Table 1

- The selected cytochrome P450 2D6 single nucleotide polymorphisms for this study.

SNP ID/namePosition referenceSNP regionGenetic variationFunctional consequencePhenotype prediction*Global MAF†
rs1080985 (CYP2D6*2)NC_000022.11:g.42132375G>CPromotor2KB upstream variantNo function-Samples = 14,996
G = 0.87 (Ref)
C = 0.13 (Alt)
rs28624811 (CYP2D6*36)NC_000022.11:g.42131531G>APromotor2KB upstream variantNo function-Samples = 55,678
G = 0.66 (Ref)
A = 0.34 (Alt)
rs1065852 (CYP2D6*4)NC_000022.11:g.42130692G>AExon 1Missense variant; splice defectDecreased functionPMSamples = 48,628
G = 0.79 (Ref)
A = 0.21 (Alt)
rs28371725 (CYP2D6*41)NC_000022.11:g.42127803C>TIntron 6Intron variant; splice defectDecreased functionIM-PMSamples = 43,504
C = 0.91 (Ref)
T = 0.09 (Alt)
rs1135840 (CYP2D6*10)NC_000022.11:g.42126611C>GExon 9Missense variantDecreased functionIM-PMSamples = 24,724
C = 0.43 (Ref)
G = 0.57 (Alt)
  • * Phenotype prediction is based on Clinical Pharmacogenetics Implementation Consortium recommendations. †Global minor allele frequency is based on Allele Frequency Aggregator project database. Alt: alternative allele, CYP2D6: cytochrome P450 2D6, ID: identification, IM: intermediate metabolizers, SNP: single nucleotide polymorphism, MAF: minor allele frequency, PM: poor metabolizers, Ref: reference allele